MedTrace Logo

Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis

NCT03745417 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-02-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Expanded Umbilical Cord Mesenchymal Stem Cells on patients with moderate to severe psoriasis. Any adverse events related to UCMSCs infusion will be monitored.The primary outcome is the improvement rate of PASI(Psoriasis Area and Severity Index) and treatment response will be computed from PASI before and after UCMSCs infusion.

Conditions

  • Mesenchymal Stromal Cells
  • Psoriasis
  • Drug Effect
  • Drug Toxicity

Interventions

BIOLOGICAL

Umbilical cord mesenchymal stem cells

Umbilical cord mesenchymal stem cells were infused intravenously at a dose of 2 million cells/kg.

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Guangdong Provincial Hospital of Traditional Chinese Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2022-08-28
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03745417 on ClinicalTrials.gov